BASEL, Switzerland, Sept. 11, 2024 (GLOBE NEWSWIRE) --
GIBF2 to invest US$ 6m in BioVersys
BV100 Phase 1 study in China expected to start in 1H 2025 in preparation for a global Phase 3 registrational study
BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant ("MDR") bacteria, announced today the strategic investment by investment firm Guangzhou Sino-Israel Bio-Industry Investment Fund 2 LLP (GIBF) of US$ 6m (approximately CHF 5.17m).
The investment aligns with BioVersys' strategic decision to expand the clinical development of its lead asset BV100 in China, to address a large unmet medical need affecting a very large patient population and offering a significant market opportunity. Infections by Carbapenem-Resistant Acinetobacter baumannii (CRAB) have become a major issue in China, with an increase in the resistance rate from 32-41% in 2005 to over 75% in 2018, associated with high mortality rates in ICUs. GIBF's support for clinical trials and its extensive network in China are expected to facilitate and accelerate the clinical development of BV100.
Onboarding China to BioVersys' planned global Phase 3 clinical trial first requires a small Phase 1 study in healthy volunteers to confirm the safety and pharmacokinetic profile of BV100 ...
